Fairtree Asset Management Pty Ltd Purchases Shares of 29,539 Smith & Nephew SNATS, Inc. $SNN

Fairtree Asset Management Pty Ltd purchased a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the second quarter, HoldingsChannel.com reports. The fund purchased 29,539 shares of the medical equipment provider’s stock, valued at approximately $1,853,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Equity Investment Corp boosted its holdings in shares of Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after purchasing an additional 285 shares during the period. Smartleaf Asset Management LLC increased its holdings in Smith & Nephew SNATS by 13.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 334 shares during the period. Cary Street Partners Financial LLC raised its position in Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after purchasing an additional 365 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Smith & Nephew SNATS by 20.0% in the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after buying an additional 387 shares during the period. Finally, Clearstead Trust LLC bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $25,000. 25.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of several research analyst reports. Canaccord Genuity Group reduced their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Finally, Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $29.06 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $30.35 and a 200 day moving average of $31.89. Smith & Nephew SNATS, Inc. has a 1 year low of $28.56 and a 1 year high of $38.79.

Smith & Nephew SNATS Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be issued a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.